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Abstract
Background: The 2017 American College of Cardiology and American Heart Association guideline defined
hypertension as blood pressure (BP) ≥ 130/80 mmHg compared to the traditional definition of ≥140/90 mmHg. This
change raised much controversy. We conducted this study to compare the impact of tight (TBPC) versus standard
BP control (SBPC) on the incidence of myocardial infarction (MI) and stroke.
Methods: We retrospectively identified all hypertensive patients in an ambulatory setting based on the diagnostic
code for 1 year at our institution who were classified by the range of BP across 3 years into 2 groups of TBPC
(< 130 mmHg) and SBPC (130–139 mmHg). We compared the incidence of new MI and stroke between the 2
groups across a 2-year follow-up. Multivariate analysis was done to identify independent predictors for the
incidence of new MI and stroke.
Results: Of 5640 study patients, the TBPC group showed significantly less incidence of stroke compared to
the SBPC group (1.5% vs. 2.7%, P < 0.010). No differences were found in MI incidence between the 2 groups
(0.6% vs. 0.8%, P = 0.476). Multivariate analysis showed that increased age independently increased the
incidence of both MI (OR 1.518, 95% CI 1.038–2.219) and stroke (OR 1.876, 95% CI 1.474–2.387), and TBPC
independently decreased the incidence of stroke (OR 0.583, 95% CI 0.374–0.910) but not of MI.
Conclusions: Our observational study suggests that TBPC may be beneficial in less stroke incidence
compared to SBPC but it didn’t seem to affect the incidence of MI. Our study is limited by its retrospective
design with potential confounders.
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Introduction
As one of the most common chronic health conditions,
hypertension affects more than 1.3 billion adults world-
wide [1] and about 75 million adults in the United States
[2]. Hypertension can affect major body organs such as
heart, brain, kidneys, and eyes and can lead to serious
complications such as myocardial infarction (MI), stroke,
end-stage renal disease, or visual impairment.
For almost three decades hypertension was defined as
systolic blood pressure (SBP) ≥ 140 mmHg or diastolic
blood pressure (DBP) ≥ 90mmHg [3]. Recently, the
American College of Cardiology (ACC) and American
Heart Association (AHA) published a new guideline de-
fining hypertension as blood pressure (BP) ≥ 130/80
mmHg, and set the BP treatment goal as < 130/80
mmHg [4]. This new guideline was based on the Systolic
Blood Pressure Intervention Trial (SPRINT), which in
2015 showed lower rates of fatal and nonfatal major car-
diovascular events and all-cause mortality when target-
ing SBP < 120mmHg [5]. There have been clinical trials
and meta-analyses showing that intensive blood pressure
control significantly lowers the stroke risk [6–8]. Regard-
ing the association of MI and BP control, there have
been mixed results. A meta-analysis by Reboldi et al.
showed no benefit in the incidence of MI compared to
stroke [8]. The ONTARGET trial by Mancia et al. also
found no significant benefit of intensive BP control on
the MI outcome [9]. On the other hand, there have been
studies that showed tight BP control might potentially
increase the risk of MI [10, 11].
The new ACC/AHA guideline has raised controversies
and the American Academy of Family Physicians re-
cently decided to not endorse it due to the lack of suffi-
cient data in systematic reviews, the lack of quality
assessments for the studies, and giving considerable
weight on the SPRINT trial while minimizing results
from other trials [12]. Because of the controversy over
the benefit of tight (TBPC) versus standard BP control
(SBPC), we analyzed the incidences of MI and stroke in
these two patient populations at our large health system.
Methods
Study design and patient population
This single-center, retrospective cohort study aimed to
assess the occurrence of new MI or stroke in patients
with TBPC (SBP < 130mmHg) versus SBPC (SBP 130–
139 mmHg). We addressed only SBP rather than both
SBP and DBP based on similar previous studies includ-
ing the SPRINT trial [5].
The data were collected and analyzed in 2018. We
accessed the health system’s data stores (for medical re-
cords) to identify all outpatient encounters regardless of
specialties (not limited to Family Medicine department)
with ICD-10 diagnostic codes for hypertension in 2013.
This resulted in 233,622 encounters in 88,456 patients.
From this group we then applied inclusion and exclusion
criteria to identify our study patients.
BPs have been measured by healthcare professionals
manually with using a sphygmomanometer and a stetho-
scope in a typical outpatient setting in the same health
system. We included patients with SBP < 140mmHg be-
tween ages 40 and 79 years. The age range was based on
the recent Centers for Disease Control and Prevention
report showing that adults between ages 18 and 44 years
mostly had hypertension under control and used antihy-
pertensive medications less often [13]. We excluded the
population greater than or equal to age 80 due to limited
life expectancy. We averaged each patient’s SBPs mea-
sured in the same year between 2013 and 2015, so that
one individual should have one averaged SBP reading
per year. We excluded patients if the annual SBP measure
was absent or if the averaged SBP fluctuated between TBPC
and SBPC during the 3 years for BP characterization
(2013–2015). We excluded patients with diabetes mellitus
because the disease is a significant risk factor and a con-
founder in MI or stroke outcome. We excluded patients
with a history of MI or stroke before 2013 because these
are the highest risk factors for recurrent MI or stroke and
we cannot assess a true incidence of new MI and stroke if
we include these patients. We also excluded patients with
MI or stroke events between 2013 and 2015. The attrition
diagram (Fig. 1) summarizes the enrollment process.
Outcome measures
The main outcome measures compared between the
TBPC and SBPC groups were any new incidence of MI
or stroke which occurred within 2 years (2016–2017).
Clinical settings of the cardiovascular outcomes included
Fig. 1 Attrition diagram of the study population
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outpatient, emergency department, and inpatient. For
ICD-10 coding, we included MI including “late effect”
codes, but we did not include angina pectoris. For stroke
we counted both ischemic and hemorrhagic strokes and
“late effect” codes. “Late effect” means residual sequelae
after the initial acute phase of the illness has resolved
[14]. We did not include transient ischemic attacks given
its potential diagnostic uncertainty. We also excluded
traumatic hemorrhages or vascular syndromes (e.g., ver-
tebrobasilar artery syndrome).
Variables
All the variables were collected through the database
sorting system on Epi Info 7 provided by the Centers for
Disease Control and Prevention (Atlanta, GA) per statis-
tician (LL). We obtained baseline demographic data such
as age, gender, race, and body mass index (BMI). We
noted smoking status, serum low-density lipoprotein
(LDL) levels, glomerular filtration rate, aspirin use, anti-
hypertensive use, and statins use. Age was categorized
by decade (40–49, 50–59, 60–69, and 70–79 years old).
Race/ethnicity was categorized as African American,
Asian, Hispanic, white, and other/unknown. For analysis,
we further dichotomized race into 2 groups of African
American and non-African American based on the re-
cent Centers for Disease Control and Prevention report
showing a relatively low percentage of hypertension
visits among African Americans compared to other races
[13]. BMI was categorized as underweight (BMI < 18.5
kg/m2), normal (BMI 18.5–24.9 kg/m2), overweight (BMI
25.0–29.9 kg/m2), obese (BMI 30.0–39.9 kg/m2), and
morbidly obese (BMI ≥ 40.0 kg/m2) based on World
Health Organization criteria [15]. Smoking status was
categorized as “never” or “ever.” Serum LDL was catego-
rized as ≥190 mg/dl or < 190 mg/dl; the former is one of
the absolute indications of statin use based on 2013
ACC/AHA guidelines [16]. Glomerular filtration rate
was categorized as ≥30ml/min/1.73 m2 and < 30ml/min/
1.73 m2; the latter is the cutoff value where primary care
physicians are recommended to refer patients to neph-
rology [17]. Use of aspirin, statins, and antihypertensives
was determined from medication orders and defined as
yes or no. In terms of counting antihypertensives, au-
thors sorted it into major category of antihypertensives,
for example, thiazide diuretic or calcium channel
blockers, and then counted each medication that falls
into each category of the antihypertensives per each pa-
tient during the enrollment period. This sorting process
was done by statistician (LL).
Adverse events
Authors believed it is important to evaluate hypotension-
related adverse events in the TBPC group. However, given
the retrospective nature of the study with using a large
cohort, we were unable to collect data on the adverse
events such as lightheadedness, dizziness, syncope, or falls
in the TBPC group. However, we addressed and counted
SBP < 90mmHg in the TBPC group to find out the inci-
dence of significant hypotension.
Statistical analysis
Sample characteristics were described using means and
standard deviations for continuous variables (SBP) and
frequencies (number and percentage) for categorical
variables (gender, race, smoking, BMI categories, use of
statin, and use of aspirin). To compare the baseline var-
iables between TBPC and SBPC groups, we conducted
chi-square tests. For multivariate analysis to determine
independent predictors for MI or stroke incidence, we
performed binary logistic regression entering only those
variables that showed significant difference between
TBPC and SBPC groups with the only exception of the
variable ‘antihypertensive use versus no use’ as this
variable was considered to be relevant for the outcomes
because antihypertensive use can modify the cardiovas-
cular outcomes. We additionally included ‘the number
of antihypertensives’ to build a different regression
model to predict outcomes with excluding ‘antihyper-
tensive use versus no use’. All statistical analyses were
performed using Epi Info 7 provided by the Centers for
Disease Control and Prevention (Atlanta, GA). A P
value < 0.05 was considered statistically significant.
Results
Baseline data
We identified 5640 patients as a final cohort for our
study (Fig. 1). Significant differences were noted in age,
race, BMI, statin use, and the number of antihyperten-
sives between the 2 groups (Table 1). More patients aged
50 to 69 years were in the TBPC group whereas the
SBPC group had significantly more patients between 70
and 79 years (P < 0.001). African Americans were less
likely to have TBPC compared to other races (P < 0.001).
The TBPC group had more normal weight and over-
weight patients whereas the SBPC group had signifi-
cantly more obese and morbidly obese patients (P <
0.001). The TBPC group had higher statin use than the
SBPC group (P < 0.05). More patients in the SBPC group
used 3 or more antihypertensive medications than those
in the TBPC group. No differences were noted in gen-
der, smoking status, serum LDL, glomerular filtration
rate, and aspirin use between the 2 groups.
Incidence outcomes
The TBPC and SBPC groups showed no difference in in-
cidence of new MI in the 2-year follow-up (Table 2).
The SBPC group had a significantly higher incidence
of stroke compared to the TBPC group (2.7% vs.
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1.5%, P < 0.010) (Table 2). This gave an absolute risk
reduction of 1.2%, and the number needed to treat of
approximately 83.
Multivariate analysis
In the logistic regression model, only increased age was
an independent predictor of MI incidence (OR 1.518,
95% CI 1.038–2.219) when ‘antihypertensive use versus
no use’ was included as one of the variables (Table 3).
However, when ‘the number of antihypertensives’ was
included in the model, increased number of antihyper-
tensives was an independent predictor of MI (OR 2.272,
95% CI 1.441–3.581) (Table 4). In terms of stroke
Table 1 Baseline data for patients with tight versus standard
blood pressure control
Variables TBPC (SBP
< 130 mmHg)
(n = 4530) N (%)
SBPC (SBP
130–139 mmHg)
(n = 1110) N (%)
P valuea
Age category < 0.001
40 to 49 years 778 (17.2) 183 (16.5)
50 to 59 years 1533 (33.8) 330 (29.7)
60 to 69 years 1466 (32.4) 339 (30.5)
70 to 79 years 753 (16.6) 258 (23.2)
Gender 0.504
Male 1917 (42.3) 482 (43.4)
Female 2613 (57.7) 628 (56.6)
Race < 0.001
African American 1235 (27.3) 406 (36.6)
Asian 152 (3.4) 26 (2.3)
Hispanic 58 (1.3) 13 (1.2)
White 2588 (57.1) 550 (49.5)
Other/unknown 497 (11.1) 115 (10.4)
BMI category < 0.001
Underweight 50 (1.1) 10 (0.9)
Normal 805 (18.4) 149 (13.8)
Overweight 1602 (36.6) 341 (31.7)
Obese 1624 (37.1) 467 (43.4)
Morbidly obese 293 (6.7) 109 (10.1)
Smoking 0.399
Ever 2195 (48.5) 521 (47.1)
Never 2333 (51.5) 586 (52.9)
Serum LDL level 0.182
≥ 190 mg/dl 22 (0.6) 9 (1.0)
< 190 mg/dl 3652 (99.4) 894 (99.0)
EGFR (race-adjusted) 0.333
≥ 30 ml/min/1.73m2 3653 (99.3) 905 (99.6)
< 30 ml/min/1.73m2 27 (0.7) 4 (0.4)
Aspirin use 0.529
Yes 1073 (23.7) 253 (22.8)
No 3457 (76.3) 857 (77.2)
Statin use < 0.05
Yes 2008 (44.3) 450 (40.5)
No 2522 (55.7) 660 (59.5)
Antihypertensive use 0.646
Yes 4328 (95.5) 1064 (95.9)
No 202 (4.5) 46 (4.1)
No. Antihypertensives < 0.001
0 202 (4.5) 46 (4.1)
1 1711 (37.8) 347 (31.3)
2 1376 (30.4) 321 (28.9)
3 or more 1241 (27.4) 396 (35.7)
aChi-square test
Boldface indicates statistical significance (p < 0.05)
Table 2 Two-year cardiovascular incidence in tight versus
standard blood pressure control
Variables TBPC (SBP
< 130mmHg)
(n = 4530) N (%)
SBPC
(SBP 130–139 mmHG)
(n = 1110) N (%)
P valuea
Myocardial infarction 0.476
Yes 28 (0.6) 9 (0.8)
No 4502 (99.4) 1101 (99.2)
Stroke < 0.010
Yes 68 (1.5) 30 (2.7)
No 4462 (98.5) 1080 (97.3)
aChi-square test
Boldface indicates statistical significance (p < 0.05)
Table 3 Multivariate analysis to predict myocardial infarction
and stroke
Variables OR (95% CI) P valuea
Myocardial infarction
Age 1.518 (1.038–2.219) 0.032
African American
(vs. other races)
1.010 (0.464–2.199) 0.981
Body mass index 0.828 (0.562–1.219) 0.338
Statin use (vs. no use) 1.408 (0.701–2.829) 0.314
Antihypertensive use
(vs. no use)
140,232.7426 (0.000- > 1.0E12) 0.969
Tight (vs. standard)
BP control
0.734 (0.339–1.588) 0.432
Stroke
Age 1.876 (1.474–2.387) < 0.001
African American
(vs. other races)
1.080 (0.677–1.722) 0.748
Body mass index 0.940 (0.742–1.192) 0.610
Statin use (vs. no use) 1.338 (0.876–2.044) 0.178
Antihypertensive use
(vs. no use)
1.911 (0.466–7.838) 0.369
Tight (vs. standard)
BP control
0.583 (0.374–0.910) 0.018
aBinary logistic regression test
Boldface indicates statistical significance (p < 0.05)
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incidence, both increased age (OR 1.876, 95% CI 1.474–
2.387) and TBPC (OR 0.583, 95% CI 0.374–0.910) were
significantly associated with stroke incidence when ‘anti-
hypertensive use versus no use’ was included as one of
the variables (Table 3). When ‘the number of antihyper-
tensives’ was included in the model, increased age (OR
1.792, 95% CI 1.406–2.284), increased number of antihy-
pertensives (OR 1.282, 95% CI 1.011–1.627), and TBPC
(OR 0.589, 95% CI 0.377–0.919) were independent pre-
dictors of stroke (Table 4).
Adverse events
Among the 4530 patients in the TBPC group, only 5
patients (0.001%) had SBP < 90 mmHg per BP readings
in the outpatient setting.
Discussion
This single-center cohort study of more than 5000
hypertensive patients evaluated the impact of TBPC
(SBP < 130mmHg) on the incidence of new MI and
stroke. We suggest that TBPC independently decreased
the incidence of stroke compared to SBPC, but did not
have an impact on MI incidence.
A retrospective study using the ACTION trial database
found the greatest difference between SBP < 130mmHg
(2.5% incidence rate) and SBP < 140mmHg (3.8% inci-
dence rate) groups in the risk of stroke [18]. The cohort
in the ACTION trial was different from ours in that
their patients had stable coronary heart disease [19]. A
meta-analysis performed by Lee et al. demonstrated that
SBP < 130 mmHg compared to SBP 130–139 mmHg
showed additional protective effect on stroke in patients
with cardiovascular risk factors but no previously estab-
lished cardiovascular disease [7]. In another meta-
analysis, Reboldi et al. found that more-tight SBP control
(< 120 mmHg), compared to less-tight SBP control (<
140 mmHg), significantly reduced stroke risk by 31%,
but no significant risk reduction was noted in MI [8].
While these results are similar to ours, Reboldi et al’s
analysis included diabetic patients and a different BP
cutoff for the 2 groups. The ONTARGET trial provided
further evidence on the significant impact of BP control
on stroke but not on MI [9]. The trial found that more
frequent achievement of target BPs (< 130/90 mmHg
or < 140/90 mmHg) resulted in significant cerebrovascu-
lar protection but not cardiac protection [9]. More re-
cent large European meta-analyses further strengthen
the evidence that more intense blood pressure control
reduces cardiovascular events [6, 20].
Why TBPC decreases the risk of stroke but not MI re-
mains unclear. Several long-term prospective population-
based studies have shown that hypertension increased the
relative risk of stroke to a greater degree than MI [21–24].
One possible hypothesis is different blood flow physiology
between the brain and heart. The brain receives a larger
fraction of cardiac output by nearly 3-fold than the heart
[25]. While most of the coronary blood flow occurs during
diastole, the cerebral blood flow occurs during systole
[26]. Therefore, cerebral blood flow might be more sensi-
tive to a change in SBP than coronary blood flow, and cor-
onary blood flow might be more sensitive to a change in
DBP than SBP. A recent multinational study supports this
hypothesis in that results showed increased risk of MI
with increased DBP whereas increased SBP did not in-
crease the risk of MI [11].
Other studies have reported different results. Verdecchia
et al. performed an open-label randomized trial and found
no difference in the incidence of MI or stroke between
TBPC (< 130mmHg) and SBPC (< 140mmHg) [27]. Their
population was similar to ours in the exclusion of diabetic
patients. Another large randomized study using the data-
base of the Hypertension Optimal Treatment trial showed
that TBPC (< 130mmHg) in patients with diabetes and
coronary artery disease did not improve cardiovascular out-
comes compared to SBPC (< 140mmHg) [28]. The AC-
CORD study conducted in 2010 also showed no difference
in fatal and nonfatal cardiovascular events between TBPC
(< 120mmHg) and SBPC (< 140mmHg) groups in diabetic
patients. More importantly, the TBPC group demonstrated
significantly higher rates of serious adverse events attrib-
uted to antihypertensive therapy [29]. Furthermore, a post
hoc analysis using the Irbesartan Diabetic Nephropathy
Trial database concluded that BP ≤ 120/85mmHg may be
associated with increased cardiovascular events [30].
Our study and the majority of cohort and prospective
studies have shown that TBPC is associated with
Table 4 Multivariate analysis to predict myocardial infarction
and stroke (Number of antihypertensives as one of the variables)
Variables OR (95% CI) P valuea
Myocardial infarction
Age 1.358 (0.929–1.986) 0.115
African American (vs. other races) 0.910 (0.416–1.991) 0.814
Body mass index 0.960 (0.904–1.019) 0.176
Statin use (vs. no use) 1.269 (0.630–2.557) 0.504
Number of antihypertensives 2.272 (1.441–3.581) < 0.001
Tight (vs. standard) BP control 0.788 (0.363–1.707) 0.545
Stroke
Age 1.792 (1.406–2.284) < 0.001
African American (vs. other races) 1.059 (0.663–1.690) 0.812
Body mass index 0.979 (0.944–1.015) 0.243
Statin use (vs. no use) 1.300 (0.849–1.990) 0.227
Number of antihypertensives 1.282 (1.011–1.627) 0.040
Tight (vs. standard) BP control 0.589 (0.377–0.919) 0.020
aBinary logistic regression test
Boldface indicates statistical significance (p < 0.05)
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decreased risk of stroke. Nevertheless, the issue of TBPC
must be addressed carefully in the clinical setting. Even
though cerebral blood flow has an autoregulation mech-
anism, the mechanism can be lost if the mean arterial
BP drops below 60 mmHg [31]. A study that targeted
BP < 130/80 mmHg for diabetic patients found intensive
BP control caused progressive reduction of cerebral
blood flow velocity [32]. According to the meta-analysis
by Thomopoulos et al., the BP-lowering treatment re-
duced cardiovascular events by 24% whereas it increased
the risk of discontinuation attributed to adverse events
by 89% [33]. Ferreira et al. recently demonstrated signifi-
cantly increased rates of cardiovascular death, heart fail-
ure hospitalization, MI, and stroke when SBP decreased
below 125mmHg [11]. In our study, only 0.001% (5/
4530) in the TBPC group showed SBP < 90 mmHg.
An interesting finding in our study is that statin use
did not independently affect MI or stroke incidence.
Based on the 2013 ACC/AHA guidelines, absolute indi-
cations for statin use include clinical atherosclerotic car-
diovascular disease, type 2 diabetes mellitus, and serum
LDL ≥ 190 mg/dl [16]. Perhaps statin use did not affect
the MI or stroke incidence in our study because we ex-
cluded patients with diabetes and those with a history of
MI or stroke. Very few patients in our study had a serum
LDL ≥ 190 mg/dl (Table 1). Another interesting finding
is that increased number of antihypertensive medications
significantly predicted both MI and stroke incidence
while the usage of antihypertensive medication itself did
not predict either MI or stroke incidence in the multi-
variate model. This can suggest that requiring more
antihypertensive medications rather than taking the
medications itself could predict higher cardiovascular
risk, or those who were prescribed many antihyperten-
sive medications would have not been adherent to the
medications.
Limitations
The major limitation of our study is that this is an obser-
vational retrospective study. Given the fact that authors
did not do any interventional measures for the patients,
strictly speaking, it might not be very appropriate to use
the terms “tight control” and “standard control”. However,
as all the patients were formally diagnosed with hyperten-
sion, authors assumed that they had received some type of
BP control intervention including lifestyle counseling from
their providers. And this would have justified our using
the terms “control.” Our study also has several other limi-
tations. Because of the retrospective design, we were not
able to completely address and remove all potential con-
founders. For example, excluding patients whose BP
showed fluctuating levels between TBPC and SBPC could
otherwise have affected the outcome. There were signifi-
cant differences in age, race, BMI, statin use, and the
number of antihypertensives between TBPC and SBPC
groups. The TBPC group was younger and had statins
prescribed more often than the SBPC group. Although
these variables were adjusted at multivariate analysis, these
differences might still have affected our findings, and we
admit that this is potentially the most major limitation of
our study, which should be criticized. Also, as we excluded
other significant risk factors of MI and stroke, such as dia-
betes and history of MI or stroke, our study population
was different from actual patients commonly seen in clin-
ical practice, which might have resulted in the relatively
rare outcome events in our study. Also, as we were not
able to review each patient’s medical record given the
large, retrospective, and electronic-based data analysis, we
were unable to collect information on the adverse events
that can potentially occur from TBPC such as dizziness,
syncope, falls, acute kidney injury, or cerebral hypo-
perfusion. However, given that only 0.001% of the TBPC
patients had SBP less than 90 mmHg, it is less likely
that many of our TBPC patients developed significant
hypotension-related complications. Also, we were un-
able to assess each patient’s medication adherence data
as we only counted the numbers of the medication pre-
scriptions which can potentially be significantly con-
founding. It also would have been more informative if
we could include the mortality and quality of life out-
comes in either group, which should be considered for
future research.
Conclusions
Our observational retrospective cohort study showed
that TBPC had a significant benefit in less stroke inci-
dence compared to SBPC, although it did not affect the
incidence of MI. Our study could help aid in the discus-
sion regarding the association of BP control and stroke
in actual clinical practice. Even though the American
Academy of Family Physicians decided to not endorse
the ACC/AHA guideline, our study shows more favor-
able result towards the SPRINT trial in terms of less
stroke incidence.
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